Transformations of Seattle Genetics by Clay Siegall

Clay Siegall is behind the co-founding of Seattle Genetics. He currently serves as the CEO and President of the company he co-founded, Seattle Genetics where he plays the role of chairman to the board of the directors. Through his expertise, experience, and excellent leadership skills, the company has launched various drugs pipeline. The drugs are made of antibodies which are responsible for the cancer treatment.


Clay Siegall has been in the forefront in helping the firm in raising finance making it secure more than $ 675 million. He has earned reputation and respect in every area he has covered in his career course. Dr. Clay Siegall before co-founding Seattle Genetics served at National Institute of Health, Bristol-Myers Pharmaceuticals Research Institute, and National Cancer Institute.


Clay Siegall has gained experience and knowledge in health industry over the years. Clay was also in the board directors of Alder BioPharmaceutical. Siegall has written and published over seventy publications and had come up with fifteen patents.


Dr. Clay Siegall has an excellent educational background. Clay received his Ph.D. in Genetics from Washington University and pursued B.S in Zoology from the world class University of Maryland. His passion for health care, drive and focus have enabled him to scale success in different heights.


On the Clay Siegall watch, Seattle Genetics has led in studying, manipulating and packaging of cancer cure drugs. It is the world leading human antibodies producing company. The antibodies produce a toxic substance to the cancer cell destroying it from inside.


In Clay Siegall leadership the company has expanded its market value to $ 10 billion. It has also provide over 900 jobs to the people. Seattle is among the high-tech biotech enterprises in the world.


The company has invested firmly in research and marketing. Seattle launched the following drugs; Adcetris which treats a Lymphatic system cancer, Hodgkin Lymphoma, 33A that operates and cure Myeloid Leukemia, the 22ME drug which targets the common bladder cancer and lastly LIVI medicine which targets treatment of breast cancer.


Seattle Genetics serves as an oncology company which has various drugs pipeline as the focus point. It focuses more on Antibody-Drug Conjugate which targets human antigens that boost human immunity in fighting against diseases.